Sanofi-Aventis stands apart from most other Big Pharma mergers. Granted, it shares many of the same drivers as previous tie-ups: looming patent expiries and hunger for size. But the unashamed political intervention was unique and points to the still delicate balance in France between commercial freedom and nationalistic pride. More importantly though, its effects may hamper Sanofi-Aventis' success on the global stage.
There's never been a pharma merger quite like it. Sanofi-Synthélabo's first approach towards Aventis SA last year was friendly....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?